1. Home
  2. NRDS vs DCTH Comparison

NRDS vs DCTH Comparison

Compare NRDS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

N/A

Current Price

$9.53

Market Cap

631.6M

Sector

Technology

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$16.19

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRDS
DCTH
Founded
2009
1988
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
631.6M
578.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
NRDS
DCTH
Price
$9.53
$16.19
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$15.00
$22.00
AVG Volume (30 Days)
569.7K
367.8K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
68.42
107.53
EPS
0.37
0.04
Revenue
$836,600,000.00
N/A
Revenue This Year
$10.13
$24.54
Revenue Next Year
$7.11
$33.15
P/E Ratio
$25.49
$397.75
Revenue Growth
21.67
N/A
52 Week Low
$7.33
$8.12
52 Week High
$16.24
$17.42

Technical Indicators

Market Signals
Indicator
NRDS
DCTH
Relative Strength Index (RSI) 46.49 57.71
Support Level $9.45 $9.98
Resistance Level $9.75 $17.42
Average True Range (ATR) 0.27 0.39
MACD -0.08 -0.20
Stochastic Oscillator 20.95 52.60

Price Performance

Historical Comparison
NRDS
DCTH

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: